Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION3: DMX-200 in focal segmental glomerulosclerosis (FSGS) on ARB background therapy
jRCT2031250150Phase 3Active, not recruiting
- Sponsor
- Dimerix
- Start
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in focal segmental glomerulosclerosis (FSGS) comparing DMX-200 + ARB with Placebo + ARB (2 arms). Primary endpoints: Percent change in urine protein/creatinine ratio at Week 35 and Slope of eGFR from baseline to Week 104. Started Sep 2025; status: active, not recruiting.
02
Drugs
repagermanium
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on jRCT2031250150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250150.